Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
-$0.06 today
- Market cap
- $784.28M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
Volume 4.75M
Average 3.58M
ARDX Common Stock Issued
Cash raised by issuing new shares.
Ardelyx, Inc.NASDAQ: ARDX
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued growth accelerates
Q1 FY2026 common stock issued of $5.44M rose 267.2% year over year, ahead of the +53.2% change in trailing-twelve-month common stock issued. Sequentially, it rose 877.0% from the prior quarter. Over 3 fiscal years it compounded at -56.6% a year.
Context
- Common stock issued amounted to 1.4% of revenue in FY2025, down 1.0 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +267.2% holds above the trailing-twelve-month pace of +53.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 5.84M USD
- Year-over-year change
- -28.2%
- 4-year CAGR
- -51.0%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.84M | -28.2% |
| FY2024 | 2024-12-31 | 8.14M | -93.2% |
| FY2023 | 2023-12-31 | 119.24M | +66.5% |
| FY2022 | 2022-12-31 | 71.63M | -29.2% |
| FY2021 | 2021-12-31 | 101.15M | — |
Common Stock Issued vs competitors
How ARDX compares with its peers on the latest reported figures
- ARDX's LTM Mar 2026 common stock issued of $9.8M is the 4th largest of the 5 companies compared; the peer median is $9.25M.
- Its year-over-year change of +53.2% is the highest of 3, against a peer median of -129.2%.
- Common stock issued amounts to 2.3% of revenue for ARDX, versus a peer median of 5.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $120.32M | -160.7% | +442.5% | 601.6% | |
| LTM Mar 2026 | $44.53M | — | — | — | |
| LTM Mar 2026 | $16.42M | — | -24.1% | 5.2% | |
| LTM Mar 2026 | $9.8M | +53.2% | -56.6% | 2.3% | |
| LTM Mar 2026 | $2.09M | -97.7% | +108.6% | 0.9% | |
| Peer median (excluding ARDX) | $9.25M | -129.2% | +108.6% | 5.2% | |
Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Depreciation & Amortization | 1.44M | 1.14M | 1.29M | 2.06M | 3.06M |
| Deferred Income Tax | (190K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.04M | 10.75M | 13.53M | 37.38M | 48.96M |
| Change in Working Capital | (11.92M) | (19.58M) | (43.39M) | (49.17M) | (31.35M) |
| Accounts Receivables | (502K) | (7.23M) | (14.3M) | (35.67M) | (14.14M) |
| Inventory | (10.37M) | (28.35M) | (21.14M) | (41.7M) | (31.92M) |
| Accounts Payables | (1.35M) | 6.58M | 279K | 4.86M | 3.24M |
| Other Working Capital | 300K | 9.42M | (8.23M) | 23.34M | 11.48M |
| Other Non-Cash Items | 4.25M | 4.84M | 4.91M | 4.05M | (1.55M) |
| Operating Cash Flow | (152.55M) | (70.04M) | (89.72M) | (44.81M) | (42.48M) |
| Capital Expenditures | (1.87M) | (55K) | (344K) | (1.01M) | (1.49M) |
| Acquisitions (Net) | (52.82M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (72.74M) | (50.33M) | (215.23M) | (195.16M) | (218.92M) |
| Sales of Investments | 125.55M | 67M | 84.32M | 177.85M | 211.46M |
| Other Investing Activities | 52.82M | 1.8M | 0 | 0 | 0 |
| Investing Cash Flow | 50.95M | 18.42M | (131.25M) | (18.32M) | (8.96M) |
| Debt Repayment | (19.44M) | (6.07M) | 22.39M | 99.45M | 48.67M |
| Common Stock Issued | 101.15M | 71.63M | 119.24M | 8.14M | 5.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 9.78M | 4.67M | (1M) | 0 |
| Financing Cash Flow | 83M | 75.34M | 146.3M | 106.59M | 54.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (18.6M) | 23.71M | (74.67M) | 43.46M | 3.07M |
| Free Cash Flow | (154.42M) | (70.1M) | (90.06M) | (45.82M) | (43.98M) |
Ardelyx, Inc.
NASDAQ:ARDX
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.